Charles Grubsztajn

Charles Grubsztajn is an experienced professional in the pharmaceutical industry. Charles currently holds the position of Chief Operating Officer at Congruence Therapeutics since May 2021. Prior to this, they served as the Chief Operating Officer at Neopharm Labs from August 2017 to May 2021. Charles also gained expertise as the Executive Vice President at Valeo Pharma Inc. from May 2016 to April 2017. In addition, they worked as a Senior Advisor at ML Partners from November 2014 to April 2017. Charles Grubsztajn also served as the Managing Partner at Griffintown Capital Partners LLC from January 2013 to January 2015. Charles held key leadership roles at MethylGene Inc. (now Mirati Nasdaq:MRTX), including President and Chief Executive Officer from September 2010 to September 2012, and Vice President of Business Development from January 2008 to September 2010. Charles Grubsztajn's career also includes serving as the Executive Director of Business Development at MethylGene from May 2005 to January 2007, and as the Associate Director of Business Development at CellCarta from June 2001 to May 2005.

Charles Grubsztajn obtained a Bachelor of Commerce in International Business from McGill University from 1993 to 1996. Charles then pursued further education at McGill University from 1996 to 2001, earning a Bachelor of Civil Law degree and an MBA with a specialization in International Business. In 2008, they obtained a certification in CLP (Certified Licensing Professionals, Inc.).